Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges. Traditional ...
Researchers conducting this trial will compare zipalertinib plus chemotherapy with chemotherapy alone in patients with previously untreated, locally advanced or metastatic non-small cell lung cancer ...
In a primary efficacy population of 85 patients, the confirmed overall response rate was 46%. The Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy ® (sunvozertinib) for ...
Exon 20 insertion mutations in non-small cell lung cancers have been a therapeutic challenge, and thus new agents targeting exon 20 mutations are a welcome addition. The study by James Chih-Hsin Yang ...
After discussions with the FDA, Takeda plans on voluntarily withdrawing Exkivity as a treatment for adults with EGFR exon 20 insertion mutation-positive, locally advanced or metastatic non-small cell ...
Results showed a statistically significant improvement in progression free survival in patients treated with amivantamab with carboplatin + pemetrexed compared with those who received carboplatin + ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback